Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.
Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Galvano A, Del Re M, Malapelle U, Chiari R, Conte P, Danesi R, Fassan M, Ferrara R, Genuardi M, Ghiorzo P, Gori S, Guadagni F, Marchetti A, Marchetti P, Midiri M, Normanno N, Passiglia F, Pinto C, Silvestris N, Tallini G, Vatrano S, Vincenzi B, Cinieri S, Beretta G. Russo A, et al. Among authors: ferrara r. Crit Rev Oncol Hematol. 2022 Jan;169:103567. doi: 10.1016/j.critrevonc.2021.103567. Epub 2021 Dec 8. Crit Rev Oncol Hematol. 2022. PMID: 34896250 Review.
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Passiglia F, Pilotto S, Facchinetti F, Bertolaccini L, Del Re M, Ferrara R, Franchina T, Malapelle U, Menis J, Passaro A, Ramella S, Rossi G, Trisolini R, Novello S. Passiglia F, et al. Among authors: ferrara r. Crit Rev Oncol Hematol. 2020 Feb;146:102858. doi: 10.1016/j.critrevonc.2019.102858. Epub 2019 Dec 28. Crit Rev Oncol Hematol. 2020. PMID: 31918343 Review.
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Passiglia F, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S. Passiglia F, et al. Among authors: ferrara r. Crit Rev Oncol Hematol. 2020 Apr;148:102862. doi: 10.1016/j.critrevonc.2019.102862. Epub 2020 Jan 25. Crit Rev Oncol Hematol. 2020. PMID: 32062311 Review.
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. De Toma A, et al. Among authors: ferrara r. Crit Rev Oncol Hematol. 2021 Apr;160:103299. doi: 10.1016/j.critrevonc.2021.103299. Epub 2021 Mar 16. Crit Rev Oncol Hematol. 2021. PMID: 33722699 Free article. Review.
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, Franchina T, Larici AR, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Novello S. Passiglia F, et al. Among authors: ferrara r. J Clin Oncol. 2021 Aug 10;39(23):2574-2585. doi: 10.1200/JCO.20.02574. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34236916
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung).
Citarella F, Takada K, Cascetta P, Crucitti P, Petti R, Vincenzi B, Tonini G, Venanzi FM, Bulotta A, Oresti S, Greco C, Ramella S, Crinò L, Delmonte A, Ferrara R, Di Maio M, Gurrieri F, Cortellini A. Citarella F, et al. Among authors: ferrara r. J Transl Med. 2024 Jul 31;22(1):714. doi: 10.1186/s12967-024-05538-4. J Transl Med. 2024. PMID: 39085889 Free PMC article.
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A. Simbolo M, et al. Among authors: ferrara r. J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29. J Pathol. 2017. PMID: 27873319 Free PMC article.
Genomics and Immunomics in the Treatment of Urothelial Carcinoma.
Mollica V, Massari F, Rizzo A, Ferrara R, Menta AK, Adashek JJ. Mollica V, et al. Among authors: ferrara r. Curr Oncol. 2022 May 12;29(5):3499-3518. doi: 10.3390/curroncol29050283. Curr Oncol. 2022. PMID: 35621673 Free PMC article. Review.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Brambilla M, et al. Among authors: ferrara r. Clin Lung Cancer. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.cllc.2023.08.004. Epub 2023 Aug 23. Clin Lung Cancer. 2023. PMID: 37775370 Free article.
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. Adashek JJ, et al. Among authors: ferrara r. Oncologist. 2020 Feb;25(2):94-98. doi: 10.1634/theoncologist.2019-0636. Epub 2019 Nov 20. Oncologist. 2020. PMID: 32043794 Free PMC article.
357 results